by Calcineurin inhibitors are immunosuppressive drugs that are used to prevent rejection in organ transplants like kidney, liver, and heart transplants. The drugs suppress the immune system by inhibiting the action of calcineurin, a calcium-dependent protein phosphatase. Calcineurin inhibitors find widespread usage as they are highly effective in organ transplant recipients with minimal toxicity. The global Calcineurin Inhibitor Market is estimated to be valued at US$ 10.07 Bn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increased adoption in organ transplant procedures
One of the key drivers for the calcineurin inhibitor market is the rising number of organ transplant procedures being performed globally. According to estimates by the Global Observatory on Donation and Transplantation, over 135,000 solid organ transplant procedures were performed in 2019 worldwide. Kidney transplants accounted for the majority of procedures. The success of organ transplantation is highly dependent on effective immunosuppression to prevent rejection. Calcineurin inhibitors such as cyclosporine and tacrolimus are an integral part of most immunosuppression regimens, driving their increased demand.
SWOT Analysis
Strength: Calcineurin inhibitors like cyclosporine and tacrolimus have been proven clinical efficacies in preventing transplant rejection. They are considered the standard of care as immunosuppressants.
Weakness: Calcineurin inhibitors have adverse effects like kidney toxicity, neurotoxicity, hypertension, increased risk of infections and malignancies with long-term use. They require therapeutic drug monitoring.
Opportunity: There is potential for development of next generation calcineurin inhibitors and combination therapies with improved safety profiles. Emerging economies with high transplant volumes present an opportunity.
Threats: Competition from alternative immunosuppressants, biosimilars, combination therapies poses pricing pressure. Stringent regulations for approval of new drugs limit approvals.
Key Takeaways
The global calcineurin inhibitor market is expected to witness high growth.
Regional analysis: North America dominates the market currently due to high insurance coverage for transplant procedures and pharmaceutical R&D. Europe and Asia Pacific regions also have high transplant volumes due to increasing organ failures and are lucrative markets.
Key players operating in the calcineurin inhibitor market include Novartis AG, Amgen, F. Hoffmann-La Roche Ltd, Pfizer Inc., Incyte Corporation, Chiesi Farmaceutici S.p.A., Astellas Pharma Inc., Sanofi SA, Bristol Myers Squibb Company, Mylan N.V., Dr. Reddy’s Laboratories Ltd., Senju Pharmaceutical Co. Ltd, Abbott, Lupin Limited, and Vibcare Pharma Pvt. Ltd. Major players are focussing on developing next generation products with improved safety profiles through combinations and derivative molecules.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
